TG-1 * Transgallaxys Forum 1

Pages: [1]

Author Topic: Andy Grove Puts Millions Into Parkinson's Fight  (Read 1632 times)

ama

  • Jr. Member
  • *
  • Posts: 1105
Andy Grove Puts Millions Into Parkinson's Fight
« on: January 11, 2008, 09:33:31 AM »

Wenn Grove 40 Millionen spenden kann, kann Forbes einen Artikel spenden. :-)

http://www.forbes.com/2008/01/10/grove-fox-parkinsons-tech-science-cz_kd_0110grove.html?partner=alerts

[*QUOTE*]
--------------------------------------------------------------------------
Sciences and Medicine

Andy Grove Puts Millions Into Parkinson's Fight

Kerry A. Dolan 01.10.08, 6:00 PM ET
BURLINGAME, CALIF. -
There's no better sign of support than a multimillion-dollar gift. Former Intel

Chairman Andy Grove told Forbes he is making a $40 million bequest to the Michael J.
Fox Foundation for Parkinson's Research to help it continue pushing for a cure to the
neurological disease.


Grove, 71, was diagnosed with Parkinson's in 2000. Since then, he has spent or
committed to spend $22 million on further research and treatments for the disease.
Some of those funds have been spent in conjunction with the Michael J. Fox
Foundation, to which Grove serves as an adviser. The additional $40 million that he
will contribute posthumously to the foundation underscores his support.
"This is a vote of confidence from me," says Grove. "It actually makes my living
collaboration more productive."

Video: Andy Grove On Parkinson's Disease
http://www.forbes.com/video/?video=fvn/healthcare/hj_grove011008

The foundation was established by the actor Michael J. Fox, who was diagnosed with
Parkinson's in 1991 when he was just 30 years old.
Grove has been increasingly active in raising money for scientific research over the past
decade. He spent seven years spearheading a fundraising campaign for scientific
research at the University of California, San Francisco, which garnered $1.6 billion in
contributions. Forbes has estimated Grove's personal net worth at about $400 million.
Both Grove and the Fox Foundation are impatient with the slow progress in developing
new drugs for Parkinson's. The mainstay drug, levadopa, is 40 years old, and merely
addresses the symptoms of Parkinson's. No drug is available to slow the progress of
Parkinson's disease, which affects 6 million people worldwide. The National Institutes
of Health spends $200 million a year on Parkinson's research, but scientists still don't
know what causes the disease.

Over the past few years, Grove has applied his characteristic intensity and razor-sharp
intellect to exploring why progress in finding treatments for neurological diseases, such
as Parkinson's, has been agonizingly slow.

"What is needed is a cultural revolution that values curiosity, follow-through a
problem-solving orientation" as well as one that puts the data collected by scientists
under broad scrutiny, Grove said in a speech in November to the annual conference of
the Society for Neuroscience. (See the Jan. 28 issue of Forbes magazine for a detailed
exploration of his campaign.)

Grove found kindred spirits in those who run the Michael J. Fox Foundation. Since it
was launched in 2000, the Michael J. Fox Foundation has spent $100 million funding
research focused on better treatments and--it hopes--a cure. "Patient relevance is
central to every decision we make. We fund research that pushes things along," says
Katie Hood, chief executive of the Fox Foundation.

The Fox Foundation has also become a powerful arbiter of emerging treatments for
Parkinson's. Edward Lanphier, chief executive of Sangamo BioSciences (nasdaq:
SGMO - news - people ), beams when he tells a reporter that his company has a $1
million grant from the Fox Foundation for a new Parkinson's treatment that has yet to
enter clinical trials.

Others wish they had that stamp of approval. "People ask us why we don't have
funding from Michael J. Fox," says John Mordock, chief of Neurologix (otcbb:
NRGX.OB - news - people ), a biotech company that has completed an early stage
gene therapy trial for Parkinson's.

These days, Grove exhibits few signs of Parkinson's other than an occasional tremor in
his right hand. He exercises religiously with the hope that it will help stave off
progression of the disease. And while he still serves as a senior adviser to Intel (nasdaq:
INTC - news - people ) management, Grove spends around half his time delving into
the details of the Parkinson's research he is funding.

Every day of action, Grove believes, can make a difference.

Hear Andy Grove and Michael J. Fox discuss the bequest in interviews with the
Forbes.com Video Network.
http://www.forbes.com/video/?video=fvn/healthcare/hj_grove011008
--------------------------------------------------------------------------
[*/QUOTE*]

See the video!
http://www.forbes.com/video/?video=fvn/healthcare/hj_grove011008

.
Pages: [1]